Olema Oncology
Ansy Mathews has a diverse work experience in the field of clinical operations, starting as a Clinical Operations Intern at Gilead Sciences in 2010. Ansy progressed through various roles at Gilead Sciences before moving on to roles at Amgen and First Wave BioPharma, Inc. Currently, they hold the position of Clinical Trial Lead at Olema Oncology since 2023. Prior to their clinical operations roles, Ansy worked as a RESEARCH ASSISTANT at the University of Cologne and as a TEAM MANAGER at Convergys Corp.
Ansy Mathews holds an MS in Biotechnology from Bharathiar University and has also completed a Certificate in Clinical Trials Design and Management from the University of California Santa Cruz.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.